Showing results (261-270 of 280) with videos related to

Sort By:
Pageof 28
ESMO Real World Data and Digital Oncology|April 3, 2026
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine careL Sellmann, D Marschner, U M Martens, et al.
British Journal of Cancer|July 14, 2011
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trialS Stintzing, L Fischer von Weikersthal, U Vehling-Kaiser, et al.
ESMO Open|April 19, 2023
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registryK Riecke, V Müller, T Neunhöffer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)J W Holch, I Ricard, S Stintzing, et al.
ESMO Open|May 17, 2025
Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA studyT Decker, C Brucker, A Engel, et al.
Applied and Environmental Microbiology|September 15, 2021
Genomes of Novel Myxococcota Reveal Severely Curtailed Machineries for Predation and Cellular DifferentiationChelsea L Murphy, R Yang, T Decker, et al.
Journal of Cancer Research and Clinical Oncology|May 13, 2014
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trialJ C von Einem, V Heinemann, L Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) studyS Stintzing, L Miller-Phillips, D P Modest, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONOM M Germani, V Heinemann, D Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306)D P Modest, I Ricard, S Stintzing, et al.
Pageof 28